Fadi Haddad, Assistant Professor of Leukemia and Co-Leader of the Chronic Myeloid Leukemia Section at The University of Texas MD Anderson Cancer Center, shared on LinkedIn:
“Grateful for the opportunity to present results from the ENABLE-1 trial evaluating ELVN-001 in chronic myeloid leukemia (CML) at the 2026 Society of Hematologic Oncology (SOHO) Annual Meeting.
It was incredibly rewarding to share these great results with such a large international hematology audience and to see the interest and discussion they generated – both during the session and in interviews following the presentation.
As we continue to advance the treatment of CML, studies like ENABLE-1 are an important part of exploring new therapeutic approaches and expanding options for our patients.
A memorable experience, and a privilege to contribute to the ongoing conversation about the future of CML therapy.”
You can also read: BCR::ABL1-Rearranged Chronic Myeloid Leukemia: Molecular Basis, TKI Resistance and Emerging Therapies
